Centenarian research — the systematic study of people who live to age 100 or beyond in good health — offers a different and complementary perspective on longevity compared to epidemiological risk factor studies. Rather than identifying what kills people earlier, centenarian studies ask what protects people against the diseases of aging for an extraordinarily long time. The findings are both predictable and surprising.
Centenarian research — studying the small fraction (approximately 1 in 10,000 in developed countries) of individuals who live to age 100 or beyond — offers a research window that epidemiological studies of risk factors and mortality cannot provide. Rather than studying what kills people, centenarian research studies what protects people from dying — across a century of biological challenges, disease exposures, and environmental stressors. The findings from the New England Centenarian Study, the Longevity Genes Project, the Okinawa Centenarian Study, and several European cohorts have produced converging insights about the biology of exceptional longevity.1
The most consistent finding across independent centenarian cohort studies is the maintenance of metabolic health and insulin sensitivity into extreme old age. Centenarians overwhelmingly demonstrate: low fasting insulin and HOMA-IR, low visceral adiposity, high circulating adiponectin (the anti-inflammatory adipokine secreted by metabolically healthy fat tissue), low triglycerides, and minimal lifetime exposure to type 2 diabetes. In the New England Centenarian Study, fewer than 10 percent of centenarians had a history of diabetes — dramatically below the general population prevalence.2
This metabolic advantage is partly genetic (variants in insulin/IGF-1 signaling pathway genes are enriched in centenarians) and partly behavioral (lifetime patterns of physical activity, moderate caloric intake, and plant-rich diet are consistently reported in centenarian populations). Separating the genetic from the behavioral contribution is methodologically challenging, but the metabolic phenotype itself — maintained insulin sensitivity and low visceral fat — appears to be the most consistent biological signature of exceptional longevity across populations.
Multiple centenarian cohort studies have found that long-lived individuals tend to have lower circulating IGF-1 levels than age-matched non-centenarians. This finding is consistent with the mechanistic evidence from model organisms: reduced insulin/IGF-1 signaling is the most robust longevity-extending intervention identified across yeast, worms, flies, and mice, and mutations in the insulin/IGF-1 signaling pathway consistently extend lifespan in every model organism studied. The paradox — that IGF-1 is required for normal growth, tissue maintenance, and muscle function, yet lower IGF-1 associates with longer life — likely reflects the difference between physiological IGF-1 (adequate for tissue maintenance, produced by healthy liver in a metabolically normal individual) and supraphysiological IGF-1 (driving excess cellular proliferation and potentially cancer-promoting mTOR activation).3
Nir Barzilai's Longevity Genes Project at Albert Einstein College of Medicine, which recruited Ashkenazi Jewish centenarians and their offspring, identified a variant in the CETP gene as one of the most consistently enriched genetic findings in this population. CETP (cholesterol ester transfer protein) facilitates the transfer of cholesterol esters from HDL to other lipoproteins. Loss-of-function CETP variants produce larger, more buoyant HDL particles and larger LDL particles — a lipoprotein size phenotype associated with dramatically lower cardiovascular risk. Drugs designed to mimic this genetic effect (CETP inhibitors including anacetrapib and evacetrapib) have had mixed results in trials, but the genetic finding establishes that lipoprotein particle size and HDL functionality — not merely HDL-C concentration — are important longevity biomarkers.4
Centenarian studies across Japan, the United States, Europe, and Sardinia consistently find that centenarians share certain psychological characteristics: positive emotional affect, high resilience in the face of adversity, lower scores on neuroticism (a personality dimension reflecting emotional instability and anxiety), strong sense of purpose and meaning, and active social engagement. The OCEAN study of Sardinian centenarians found that conscientiousness — the tendency toward self-discipline, organization, and goal-directed behavior — was the personality trait most consistently associated with exceptional longevity, with a biological mechanism likely operating through better lifetime health behaviors and lower HPA axis reactivity.5
Whether these psychological traits cause longevity (through their effects on HPA axis regulation, health behavior, and social connection biology) or are consequences of selective survival (psychologically resilient people surviving traumatic events that eliminate their less resilient peers) is difficult to disentangle. The most likely answer is both: psychological resilience provides biological protection through multiple mechanisms, and the experience of outliving one's cohort selects for individuals with inherent stress-buffering capacity.
